Member Info for EmeraldCarrots

59 plus machines in daily use minimum in total. Note in countries like Italy and France (RNS dated 27/3/2025) I have only counted 1 machine, rather than 2 as this may be only for testing it for possible use). Do Genedrive delibarately make it difficult to find this out. I have a spreadsheet and believe me it is not easy going though all the RNS's of the last 3 years. In a few cases it's easy to count a hospital twice. This is what I make it:-

Breakdown.

England 22

Scotland 3

Ireland 1

Italy 1

Saudi Arabia 1

France 1

Austria 1

Greece 1

Turkey 1

The Netherlands 1

==========

33 Nr. Hospitals.

All IMHO.

The MT-RNR1 should be in the news regularly from now on. I also expect news from Saudi Arabia, Italy and Ireland. Not sure about France, Austria, Greece, Turkey and the Netherlands which have been mentioned previously. The Scottish rollout and the Saudi Arabian news should spur other Countries on as they may feel they are being left behind in the genomic testing revolution.

All IMHO.

Investors Meet Company

The Company is further pleased to announce that the Company's CEO, Peter Collins and its Finance Director, Sinead Armstrong will provide a live presentation relating to the Investor Presentation and Q&A via Investor Meet Company on 26 November 2025 at 14:00 GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 25 November 2025 at 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet CELLBXHEALTH PLC via:

https://www.investormeetcompany.com/cellbxhealth-plc/register-investor

Companies on to place orders with us. Quite why, to date, no Immunotherapy companies other than immatics are using the CTC's Parsortix can catch from a standard blood sample to help select suitable candidates for cancer treatment is truly astounding. Astounding and extremely sad for cancer research. They really need to wake up.

All IMHO.

Stephen11.

"- Hospitals aren’t buying “one or two units” — they’re integrating it as standard of care. ".

=========================

I want to know how many MT-RNR1's are in each hospital. That is important information. It seems to be two at minimum. A conservative number is 28 machines so far in a total of 17 Hospitals Worldwide IMHO.

=========================

I have assumed only 1 in some hospitals abroad that are, I assume, only evaluating it at the moment. Otherwise it of course would be 34 machines in use at minimum.

Stephen11.

"- Hospitals aren’t buying “one or two units” — they’re integrating it as standard of care. ".

=========================

I want to know how many MT-RNR1's are in each hospital. That is important information. It seems to be two at minimum. A conservative number is 28 machines so far in a total of 17 Hospitals Worldwide IMHO.

I make it there are 17 hospitals currently using the MT-RNR1, with total of approximately 28 machines installed. International installations include at least one in Italy and one in Saudi Arabia. Does not include Spain, France, Austria, Greece, Kuwait and Turkey which were mentioned in the interim results to 31st December 2022, but no mention since.

All hospitals that now use the MT-RNR1's have ar least two machines? Seems to make sense in case there is an issue with one, or two tests are needed at the same time.

https://www.nhscfsd.co.uk/news/new-genetic-test-aims-to-prevent-hearing-loss-for-babies-in-scotland/

Truthfactory.

I’m an FCA authorised family office so I see most of the Placings.

==================

Very interesting indeed. Fingers crossed this is the start of realising the true financial potential of the Parsortix machine. We have Immatics using the machine in 3 of their cancer drug trials, one is already in phase 3 and another has just moved up to phase 2. Illumina are on side confirming "dual analysis" finds about twice as many cancer biomarkers as CtDna analysis alone. What more does the market want? The sp to me is absolutely crazy. I believe your clients will be very happy indeed in several months time, as I expect I will too.

https://immatics.com/our-pipeline/

All IMHO.

The placing is practically done so the re-financing is almost there. As the RNS says it was oversubscribed. Also we have a new major shareholder with 29.9%. What a deal they got! Hopefully the contacts will start to come in now with the new management. There is massive potential here which has not been unlocked.

Woops. I forgot this RNS about Roche:-

https://www.lse.co.uk/rns/CLBX/cellbxhealth-presents-proof-of-concept-study-dwro0kgms0rwtkg.html

RNS mentions them, but until now there was no official mention of them I believe. Any other multi billion Plc's they forgot to mention??? LOL!

"Supported by a growing network of commercial and strategic partnerships, near-term objectives include completion of proof-of-concept and validation studies with Roche and Myriad". !!!!!!!!!!!

Cancer drug trials. I can't find out exactly what they use it for as it is not in the public domain as far as I can see. The 3nr. Anzu-cel(IMA 203) trials target a protein that is SOMETIMES diplayed by cancer cells, sometimes not. So of course one needs to find this out or the drug won't work. Obviously Immatics are analysisng the CTC's. Presumably to see if the protein is displayed on the CTC's as well as the solid tumor sample. Then you have the best candidate. BUT Immatics are just one Company that does Immunotherapy. There are loads more. Proteins are often the target of these drugs. I find it completely mad other Immunotherapy Companies have not yet cottoned on to what Immatics are doing. One trial is in phase 3. That says it all. Competitors to Immatics surely will be doing the same in due course. Seems complately obvious.

https://immatics.com/our-pipeline/

All IMHO.

Truthfactory.

"The placing was oversubscribed and we got scaled back."

==================

Erm, the placing was not available to individual investors, so again what are you talking about? Who is "we"? Do you work for an investment house or something? Or are you talking nonsense?

Anzu-cel(IMA 203) trials.? This is key. One trial is in phase 3 and one in phase 2. If so CLBX is undervalued by tens of millions IMHO.

https://immatics.com/our-pipeline/

What if Immatics can't move on from their phase 3 cancer drug trial without the Parsortix machine? Plus they have two other trials that use Parsortix, one in phase 2. Raving mad.

https://immatics.com/our-pipeline/

================

I believe Immatics at MINIMUM use the Parsortix machine to help select the most suitable candidates for their 3nr. Anzu-cel(IMA 203) trials.

But it may be far more than that. They need to test the cancer cells to see if a certain protein is showing as the drug targets this protein. They obviously do this from analysing solid tumour samples at minimum. But what if they also test the live, intact, uncontaminated cancer circulating tumor cells the parsortix machine can catch? That is what the machine is for. Maybe the information they get from the CTC's is vital to the process??????

Food for thought.

All IMHO.

What if Immatics can't move on from their phase 3 cancer drug trial without the Parsortix machine? Plus they have two other trials that use Parsortix, one in phase 2. Raving mad.

https://immatics.com/our-pipeline/

Mad.

Truthfactory.

I got scaled back by 2/3

===============

What are you talking about?

Benjamin Hart as Non-executive Director. Benjamin joins the board as representative of Acacia Partners an existing Shareholder that will hold 29.9% following completion of the Fundraising.

=====================

A 29.9% stake. Interesting. About time a serious player woke up and realised what we have. The valuation of Cellbxhealth to me is completely insane.